Merck's New Products And Solid Pipeline As Growth Drivers
Zacks Investment Research | Oct 10, 2016 09:10PM ET
We issued an updated research report on Merck & Co., Inc. (NYSE:MRK) on Oct 7.
The leading pharmaceutical company has made significant progress with its pipeline and is working on bringing new products to market. Merck has more than 10 candidates in phase III development. The company has prioritized its pipeline so that candidates with the highest potential get the required support. Some of its important pipeline candidates include MK-0859 (anacetrapib – cholesterol management), verubecestat (Alzheimer’s disease), Zinplava (bezlotoxumab) and MK-8835 (ertugliflozin, type II diabetes).
Meanwhile, Merck’s new products are performing well. Products that should contribute significantly to revenues include cancer drug Keytruda, fertility drug Elonva, Simponi (treatment of certain inflammatory diseases), Dulera (asthma), and Daxas (chronic obstructive pulmonary disease). Keytruda is the first anti-PD-1 therapy to gain FDA approval and is being studied for more than 30 types of cancer. Keytruda sales should receive a boost with approval for additional indications especially in the first-line lung cancer setting. Failure of Bristol-Myers Squibb Company’s ) Opdivo in the first-line lung cancer setting should give an advantage to Keytruda, if and when it is approved in this indication.
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.